Abstract
Immune escape is a hallmark of cancer development and metastasis. Regulatory T cells (Treg) are potent inhibitors of cancer immune surveillance but also prevent inflammation-driven tumorigenesis. The study by Wolf and colleagues, which was published in the February 2003 issue of Clinical Cancer Research, showed the expansion of Treg in solid cancer patients, providing a deeper understanding of cancer immune escape mechanisms that later set the stage for the development of scientific breakthroughs in cancer immunotherapy. Clin Cancer Res; 21(12); 2657–9. ©2015 AACR.
See related article by Wolf et al., Clin Cancer Res 2003;9(2) Feb 2003;606–12
- Received February 5, 2015.
- Accepted February 20, 2015.
- ©2015 American Association for Cancer Research.
June 2015
Volume 21, Issue 12
Volume 21, Issue 12
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research
Jump to section
Advertisement